AzTrials
AzTrials

Heart Failure, SystolicNCT07050706

The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure

An observational study of Heart Failure, Systolic, run by The University of Hong Kong-Shenzhen Hospital at 1 site in China.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

Pathological cardiac hypertrophy is characterized by abnormal cardiomyocyte metabolism, reduced myocardial contractility, and dysregulated synthesis of myocardial contractile proteins. This pathological process leads to progressive impairment of cardiac function and ultimately progresses to heart failure. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Heart Failure, Systolic
How many people
50 participants
Where
1 siteChina
Study dates
1 Jan 2025to 31 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: This study evaluated whether serum PRMT5 levels could predict echocardiographic parameters in healthy controls and heart failure patients. A total of 50 participants in the healthy group and 50 in the heart failure group completed the study.

Who may be able to join

  • Healthy group: Aged ≥18 years (both sexes), systolic blood pressure (SBP) ≤120 mmHg and diastolic blood pressure (DBP) ≤80 mmHg, no history of cardiovascular diseases, ejection fraction (EF) ≥50%.
  • Heart failure group: Aged ≥18 years (both sexes), EF ≤50%.

Who cannot join

  • Exclusion criteria for healthy people: people with other underlying diseases or congenital diseases are not included in the study.
  • Exclusion criteria for patients with heart failure: patients with heart failure other metabolic diseases or congenital diseases were excluded from the study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site

  • the University of Hongkong-Shenzhen Hospital

    Shenzhen, Guangdong, 518033

Other trials in China

About this study

Official title: Study on the Correlation Between Serum PRMT5 Level and Cardiac Structural and Functional Indicators in Patients With Heart Failure

Pathological cardiac hypertrophy is characterized by abnormal cardiomyocyte metabolism, reduced myocardial contractility, and dysregulated synthesis of myocardial contractile proteins. This pathological process leads to progressive impairment of cardiac function and ultimately progresses to heart failure. Previous studies have demonstrated that PRMT5 exerts a significant inhibitory effect on heart failure, yet its clinical significance in the context of heart failure remains undefined. In this study, we hypothesized that serum PRMT5 may serve as a biomarker to predict cardiac structural parameters and functional indices. Therefore, we aim to analyse the correlation between serum PRMT5 levels and the following parameters-LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT on the first day when participants are enrolled in this study.

Read the detailed description

The aim of this study is to collect blood samples from both healthy controls and heart failure patients and to clarify the correlation between serum PRMT5 levels on the first day of enrollment and cardiac ultrasound indicators. Serum PRMT5 levels are measured by means of enzyme-linked immunosorbent assay (ELISA). Left ventricular posterior wall thickness at end-systole (LVPWs), Left ventricular posterior wall thickness at end-diastole (LVPWd), left ventricular internal diameter at end-systole (LVIDs), left ventricular internal diameter at end-diastole (LVIDd), interventricular septum at end-systole (IVSTs) and interventricular septal septum at end-diastole (IVSTd) are measured on the first day of enrollment via echocardiography. Ejection fraction (EF), fractional shortening (FS), left ventricular mass index (LVMi), and relative wall thickness (RWT) are subsequently calculated based on LVIDd, LVPWd, and IVSTd values. Finally, the correlations between serum PRMT5 levels and the following indicators are analyzed: LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT.

Keywords
PRMT5, Heart failure, cardiac function and cardiac structure
Medical subject headings
Heart Failure, Systolic, Heart Failure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Serum PRMT5 level at baseline

    Serum PRMT5 level is analysed at the day of informed consent agreement and blood sampling

    Measured: Baseline (day of informed consent agreement and blood sampling)

  2. LVIDs level at baseline

    Left ventricular internal diameter at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

    Measured: Baseline

  3. LVIDd level at baseline

    Left ventricular internal diameter at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

    Measured: Baseline

  4. LVPWs level at baseline

    left ventricular posterior wall at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

    Measured: Baseline

  5. LVPWd level at baseline

    left ventricular posterior wall at diastole state is measured at the day of informed consent agreement and cardiac ultrasound examination

    Measured: Baseline

  6. IVSTs at baseline

    Interventricular septum at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

    Measured: Baseline

  7. IVSTd at baseline

    Interventricular septum at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination

    Measured: Baseline

  8. EF at baseline

    Ejection fraction is calculated according to the formula below:

    1. EF=(LVEDV-LVESV)/LVEDV*100%;
    2. LVEDV=(7.0*LVIDd^3)/(2.4+LVIDd)
    3. LVESV=(7.0*LVIDs^3)/(2.4+LVIDs)

    Measured: Baseline

  9. FS at baseline

    Fractional shortening is calculated based on the formula below:

    FS=(LVIDd-LVIDs)/LVIDd*100%

    Measured: Baseline

  10. LVMi at baseline

    Left ventricular mass index is calculated according to the formula below:

    1. LVMi(g/m^2)=LVM/BSA;
    2. LVM(g)=LVM=0.8×1.04×[(LVIDd+IVSd+LVPWd)^3-LVIDd^3]+0.6;
    3. BSA(m^2)=0.007184×W^0.425×H^0.725 (W: Weight, kg; H: Height, cm)

    Measured: Baseline

  11. RWT at baseline

    Relative wall thickness is calculated according to the formula below:

    RWT=2*(IVSd+LVPWd)/LVIDd

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jul 2025
  2. Study start1 Jan 2025
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07050706
Sponsor's protocol ID
PRMT5 and Heart Failure
Other IDs
82300446, 2022A1515111093, RCBS20231211090745071
Status last verified
Jun 2025
First submitted
13 Jun 2025
Last updated
3 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Heart Failure, Systolic, run by The University of Hong Kong-Shenzhen Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 3 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Serum PRMT5 level at baseline (time frame: Baseline (day of informed consent agreement and blood sampling)). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07050706.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in